Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice

Cancer Gene Therapy

Volumn 16, Issue 4, 2009, Pages 291-297

  Kulu, Y ^a   Dorfman, J D ^a   Kuruppu, D ^a   Fuchs, B C ^a   Goodwin, J M ^a   Fujii, T ^a   Kuroda, T ^a   Lanuti, M ^a   Tanabe, K K ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biodistribution; Herpes simplex virus; hrR3; Peritoneal metastases; Viral oncolysis

Indexed keywords

ONCOLYTIC HERPES SIMPLEX VIRUS 1; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; HEART; HUMAN; HUMAN CELL; INTESTINE; KIDNEY; LD 50; LIVER; LUNG; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SPLEEN; SURVIVAL TIME; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; HAPLORHINI; HERPESVIRUS 1, HUMAN; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LETHAL DOSE 50; MICE; ONCOLYTIC VIROTHERAPY; PERITONEAL NEOPLASMS; TREATMENT OUTCOME; TUMOR BURDEN;

ANIMALIA; HUMAN HERPESVIRUS 1; MUS; SIMPLEXVIRUS;

EID: 62549133085     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.83     Document Type: Article

References (35)

1. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89: 1545-1550.
2. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989; 63: 364-367.
3. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006; 243: 212-222.
4. Sugarbaker PH, Cunliffe WJ, Belliveau J, de Bruijn EA, Graves T, Mullins RE et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 1989; 16(4 Suppl 6): 83-97.
5. Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res 1996; 82: 79-100.
6. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22: 3284-3292.
7. Rothenberg ML, Liu PY, Braly PS, Wilczynski SP, Hannigan EV, Wadler S et al. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial. J Clin Oncol 2003; 21: 1313-1319.
8. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62: 196-205.
9. Yoon SS, Carroll NM, Chiocca EA, Tanabe KK. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg 1998; 228: 366-374.
10. Carroll NM, Chiocca EA, Takahashi K, Tanabe KK. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 1996; 224: 323-329; discussion 9-30.
11. Yoon SS, Nakamura H, Carroll NM, Bode BP, Chiocca EA, Tanabe KK. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J 2000; 14: 301-311.
12. Delman KA, Bennett JJ, Zager JS, Burt BM, McAuliffe PF, Petrowsky H et al. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther 2000; 11: 2465-2472.
13. Nakamura H, Kasuya H, Mullen JT, Yoon SS, Pawlik TM, Chandrasekhar S et al. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest 2002; 109: 871-882.
14. Kuruppu D, Brownell AL, Zhu A, Yu M, Wang X, Kulu Y et al. Positron emission tomography of herpes simplex virus 1 oncolysis. Cancer Res 2007; 67: 3295-3300.
15. Mullen JT, Donahue JM, Chandrasekhar S, Yoon SS, Liu W, Ellis LM et al. Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer 2004; 101: 869-877.
16. Nakamura H, Mullen JT, Chandrasekhar S, Pawlik TM, Yoon SS, Tanabe KK. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 2001; 61: 5447-5452.
17. Mullen JT, Tanabe KK. Viral oncolysis. Oncologist 2002; 7: 106-119.
18. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletionmutant. Virology 1988; 166: 41-51.
19. Reynolds P, Dmitriev I, Curiel D. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Therapy 1999; 6: 1336-1339.
20. Mullen JT, Kasuya H, Yoon SS, Carroll NM, Pawlik TM, Chandrasekhar S et al. Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann Surg 2002; 236: 502-512; discussion 12-3.
21. Kasuya H, Kuruppu DK, Donahue JM, Choi EW, Kawasaki H, Tanabe KK. Mouse models of subcutaneous spleen reservoir for multiple portal venous injections to treat liver malignancies. Cancer Res 2005; 65: 3823-3827.
22. Kemeny N, Daly J, Oderman P, Shike M, Chun H, Petroni G et al. Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol 1984; 2: 595-600.
23. Kasuya H, Nishiyama Y, Nomoto S, Hosono J, Takeda S, Nakao A. Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer. J Surg Oncol 1999; 72: 136-141.
24. Coukos G, Makrigiannakis A, Montas S, Kaiser LR, Toyozumi T, Benjamin I et al. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther 2000; 7: 275-283.
25. Bennett JJ, Delman KA, Burt BM, Mariotti A, Malhotra S, Zager J et al. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther 2002; 9: 935-945.
26. Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999; 5: 881-887.
27. Wakimoto H, Johnson PR, Knipe DM, Chiocca EA. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Therapy 2003; 10: 983-990.
28. Suzuki T, Yanagi K, Ookawa K, Hatakeyama K, Ohshima N. Blood flow and leukocyte adhesiveness are reduced in the microcirculation of a peritoneal disseminated colon carcinoma. Ann Biomed Eng 1998; 26: 803-811.
29. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743.
30. Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial.[see comment]. World J Surg 2001; 25: 985-990.
31. Yonemura Y, de Aretxabala X, Fujimura T, Fushida S, Katayama K, Bandou E et al. Intraoperative chemo-hyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology 2001; 48: 1776-1782.
32. Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC. Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res 1981; 41: 1096-1099.
33. Panasiak W, Oraczewska A, Luczak M. Influence of hyperthermia on experimental viral infections in vitro. Adv Exp Med Biol 1990; 267: 471-475.
34. Szmigielski S, Luczak M, Janiak M, Kobus M, Laskowska B, de Clercq E et al. In vitro and in vivo inhibition of virus multiplication by microwave hyperthemia. Arch Virol 1977; 53: 71-77.
35. Jacobson JG, Leib DA, Goldstein DJ, Bogard CL, Schaffer PA, Weller SK et al. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 1989; 173: 276-283.